Compare Merck & Co., Inc. (MRK) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Nomura Holdings Inc — how do they compare? Merck & Co., Inc. trades at $125.97 (market cap $307.25B), while Nomura Holdings Inc trades at $9.4 (market cap $27.46B). The key difference: Merck & Co., Inc. is far larger — about 11.2× Nomura Holdings Inc's market cap, and Nomura Holdings Inc pays the higher dividend (3.45%). Which is the better fit depends on your goals.
| MRK | NMR | |
|---|---|---|
Market Cap | $307.25B | $27.46B |
Sector | Health | Financials |
52-Week High | $129.52 | $10.04 |
52-Week Low | $77.60 | $6.39 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Nomura Holdings (NMR) trades at $9.81, up 4.36% with a bullish technical signal from moving averages. The company reported record annual profit of $340.74 billion for 2025, with revenue growing to $1.66 trillion and profit margin expanding to 20.49%. Recent news highlights strong wholesale revenue growth exceeding 30% and strategic acquisitions in US asset management. The stock trades at a P/E of 12.77, below industry averages, suggesting potential undervaluation.
Outlook remains positive with continued wholesale business momentum and global expansion initiatives. Key risks include integration costs from recent acquisitions and potential market volatility. Analyst consensus shows 33% buy ratings with no sell recommendations, indicating cautious optimism. The combination of reasonable valuation and strong fundamental performance supports potential upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
